BioInvent and Servier have entered into an antibody collaboration on an oncology target involved in tumor cell metabolism provided by Servier.
BioInvent will receive a licensing fee, research support, and potential milestone payments of more than $14 million as well as royalty on future sales of the product.
Under the terms of the agreement Servier will engage BioInvent to screen its n-CoDeR library for antibodies specific to the undisclosed target. Servier will also have access to BioInvent’s in-house pre-clinical capacities in selecting an antibody candidate for development. “The Bioinvent n-CoDeR library will be used in combination with a functional assay set up at Servier to select antibody candidates,” explains Svein Mathisen, president and chief executive officer of BioInvent.
Release Date: Jan. 4, 2012